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Abstract
Background: Epidermal growth factor receptor (Egfr) has been the target of several drugs for cancers. The potential
gender differences in genes in the Egfr axis have been suggested in humans and in animal models. Female and
male mice from the same recombinant inbred (RI) strain have the same genomic components except the sex
difference. A population of different RI mouse strains allows to conduct precise analysis of molecular pathways and
regulation of Egfr between female and male mice.
Methods: The whole genome expression profiles of 70 genetically diverse RI strains of mice were used to compare
three major molecular aspects of Egfr gene: the relative expression levels, gene network and expression quantitative
trait loci (eQTL) that regulate the expression of Egfr between female and male mice.
Results: Our data showed that there is a significant sex difference in the expression levels in kidney. A considerable
number of genes in the gene network of Egfr are sex differentially expressed. The expression levels of Egfr in mice
are statistical significant different between C57BL/6 J (B6) and DBA/2 J (D2) genotypes in male while no difference
in female mice. The eQTLs that regulate the expression levels of Egfr between female and male mice are also
different. Furthermore, the differential expression levels of Egfr showed significantly different correlations with two
known biological traits between male and female mice.
Conclusion: Overall there is a substantial sex difference in the Egfr pathways in mice. These data may have
significant impact on drug target design, development, formulation, and dosage determinant for women and men
in clinical trials.
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Background
The purpose of this work is to systematically investigate the
sex differences of epidermal growth factor receptor (Egfr) in
the kidney using high quality data from a population of
mouse recombinant inbred (RI) strains. Sex differences
have been brought to the attention of the public and health
research community [1–3], and sex disparities in health
throughout the lifespan of humans or mice have been
documented [2, 3].
In humans, EGFR has been reported as an important
player in pathways of kidney diseases. Liang et al.
reported the inhibitory effect of silibinin on EGFR
signal-induced renal cell carcinoma progression via
suppression of the EGFR/MMP-9 signaling pathway [4].
The effect of EGR on renal cell carcinoma was also
reported by others [5, 6]. EGFR activation is required to
induce the renal fibrotic genes [7, 8]. EGFR has been
received great attention in cancer research because of its
connection to cancer development [9, 10]. Drugs targeting
the EGFR pathway have been developed in recent years,
and some clinic trials are underway. For example, Erlotinib,
an EGFR and tyrosine kinase inhibitor, have been used for
the treatment of kidney, lung, advanced adenocarcinoma of
the oesophagus and gastro-oesophageal junction and
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hepatocellular carcinoma cancers [11, 12]. Lapatinib
ditosylate (LAP), an anti-EGFR drug, has been used
for treatment of gastro-oesophageal cancer and renal
cancer [13, 14]. Ramucirumab has been used as
monotherapy for previously treated advanced gastric or
gastro-oesophageal junction adenocarcinoma [15–18].
While the drugs based on anti EGFR are in development
and clinical trial stage, its gender specificity should be
thoroughly investigated.
The potential gender differences in genes in the Egfr
axis have been suggested in humans and in animal models
[19–27]; however, the gender specificity on the molecular
pathways has yet to be understood. At present, a system-
atic investigation of sex specificities in the Egfr axis, either
in humans or animal models, has not been reported.
Recently, substantial progress has been made in elucidat-
ing how diverse sex specific systems are integrated into
developmental gene networks using animal models. In
particular, the RI strains derived from C57BL/6 J (B6) X
DBA/2 J (D2) have been used for studies of sex specific
traits and genetic regulations [20–22]. Sex specific gene
expressions profiling have been analyzed for the liver and
other tissues [23–25]. Therefore, we believe that our opti-
mized approach discloses information on sex differences
in the Egfr axis that will eventually impact the manage-
ment of all drug design and clinical trials in many diseases
including cancer.
Several recent publications showed the sex specificity
[20, 21, 24, 26] and tissue specificity [25, 27, 28] of gene
expression levels or the association of gene expressions.
Recent study indicated that the relative expression levels,
gene network and eQTLs that regulate the expression of
Egfr in liver are different between female and male mice
[29]. We hypothesize that at least one step in the Egfr
molecular pathway in kidney of the male is different
from that of the female mice. We first investigated
whether the expression levels of Egfr in the kidney is
different between female and male mice. We then deter-
mined whether the gene network of Egfr between female
and male mice are the same. We finally examined the
genetic loci that regulate the expression of Egfr in
females and males.
Methods
Expression levels of Egfr
For the expression data of Egfr and its associated genes,
we collected the expression data of Egfr axis from whole
genome expression data of the mouse kidney [29]. All data
are from GeneNetwork (http://www.genenetwork.org/
webqtl/main.py) and are available to the public. We used
the Actin beta (B) as controls for the expression level of
Egfr. The data set of gene expression profiles of mouse
kidney at GeneNetwork were validated using sex specific
probe sets such as X inactivation-specific transcript (Xist)
and Dead/h box 3, y-linked (Dby) [29]. When multiple
probes are presented for a gene, the probe with the high-
est expression level was chosen for the analysis while the
others were used as references.
Data set for analysis of gene expression profiles
In this study, we used the Mouse Kidney M430v2 female
and male (Aug06) RMA Database from the GeneNetwork
(http://www.genenetwork.org/webqtl/main.py). RMA
stands for statistical method of robust multi-array average
for the raw data analysis [21] The data set includes mRNA
expression in the adult kidney of both sexes of 70 genetic-
ally diverse strains of mice including 54 BXD RI strains, a
set of 15 inbred strains, and 1 F1 hybrid: D2B6F1. Kidney
samples were processed using a total of 153 Affymetrix
Mouse Expression 430 2.0 arrays. Kidneys from two to six
animals per strain were pooled. Forty-two (31 BXD,
D2B6F1 and 10 inbred strains) are represented by male
and female samples [21].
While samples of both sexes are collected at similar age,
performed with same microarray platform, and grown in
the same environment, most of them are from different RI
strains. However, these RI strains are all derived from the
same two progenitors. Also, the gene expression profiles
of both the female and male progenitors are generated
separately.
The association of the expression levels of Egfr between
female and male mouse populations
The association analysis was conducted using the method
as previously reported [23, 29, 30]. R values were com-
pared between female and male mice, following standard
criteria for the strong, correlation, and none correlation
[29]. Unless noted in the figure legends, when the R value
was equal or more than 0.7 or −0.7, the correlation was
regarded as strong positive or negative. When the R value
was between 0.50 and 0.69 or −0.50 and −0.69, the correl-
ation existed but was not strong. When the R value was
between 0.3 and 0.49 or −0.30 and −0.49, the correlation
was weak. Any R value between 0 and 0.29 or 0 and −0.29
was regarded as none-correlation [29, 30].
Gene network construction
The gene networks were constructed using application
tools in GeneNetwork. We constructed the gene net-
work based on the Network Graph in combination with
the Correlation Matrix [29]. For the Correlation Matrix,
the Pearson product-moment correlations (the standard
type of correlation) were used for the calculation of cor-
relations [30, 31]. For each sex in each pair of samples,
both the Network Graph and Correlation Matrix were
obtained with the same set of parameters or criteria. For
example, for the Line Threshold in the Network Graph,
absolute values greater than 0.30 were used across all
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samples. The Spring Model layout (force reduction) was
used for the graphic method for all graphic samples.
Transcriptomic loci (eQTL) that regulates the expression
level of Egfr in female and male mice
Transcriptome mapping with GeneNetwork was used
to identify the chromosomal regions that affect the
expression of Egfr in female and male mice, which
includes three major steps. First, Egfr probes of gene
expression were identified from female and male strains
of tissues. Second, interval mapping was done to
establish Egfr transcriptome maps for the entire gen-
ome. Permutations of 5000 tests were used to assess
the strength and consistency of the linkages. Third,
genomic regions and locations on chromosomes were
compared [30–32].
Results
Expression levels of Egfr between female and male in
mouse kidney
Basical statistical analysis was conducted with data of
gene expression of Actin B and Egfr in both sexes from
a total of 43 strains [29]. Five probes for Actin B on the
Affymetrix Mouse Genome 430 2.0 array chip was iden-
tified. The Probe of 1436722_a_at was chosen for the
analysis because its high expression level and it contains
exon 3, 4, 5 and proximal 3′ UTR. Figure 1a and b
showed the expression levels of Actin A in female and
male mice of different strains. The P value from the T
test between female and male is 0.55 and the R value
from correlation analysis is 0.25.
Seven probes for Egfr were found from data from the
Affymetrix Mouse Genome 430 2.0 array chip. The
Probe 1460420_a_at was chosen for the analysis because
its high expression level. Figure 2a and b shows the
expression levels of Egfr in female and male mice of dif-
ferent strains. For Egfr, the P value from T test between
female and male mice is 0.00 and the R value is −0.05.
Thus, there was no sex difference in the expression
level of Actin B in kidney while there was a significant
sex difference in the Egfr expression levels in these
mouse strains.
Gene network of Egfr between female and male in mouse
kidney
With Probe 1460420, the top 50 probes of genes with
expression levels most correlated to that of Egfr were
identified from the mouse data of Mouse kidney
M430v2 Male (Aug06) RMA Database. These probes
represent genes with diversity of biological functions
(Additional file 1: Table S1).
As shown in Fig. 3a, Egfr is either positively or nega-
tively correlated to the top 50 probes of genes. The
expression of mouse Egfr is strongly positively correlated
to ribosomal protein S4, X-linked (Rps4x) and zinc inger
protein 261 (Zfp261); it is strongly negatively correlated
to dedicator of cytokinesis 9 (Dock9). In order to com-
pare the correlation of these genes to Egfr in female
mice, we then constructed a gene network using the
same probes from female gene expression profiles of the
kidney (Fig. 3b).
Fig. 1 Expression levels of Actin B in kidney between female and male mice in BXD strains. Numbers on left vertical bar are for the relative levels
of expression of Actin B. The information of strains and names of standard inbred strains are listed under the horizontal bar. a. The expression
levels of Actin B in kidney of female mice. b. The expression levels of Actin B in kidney of male mice
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Several differences in the gene network of the kidney
were found between female and male mice. In males, Egfr
showed a strong negative correlation with Dock9 but in
females, such a negative correlation did not appear. In
males, Egfr showed a negative correlation with clavesin 1
(retinaldehyde binding protein 1-like 1) (Clvs1); HIF1
alpha hypoxia growth and transformation-dependent
protein, proapoptotic (Fam162a); neuropilin 1 (Nrp1);
proteoglycan 1, secretory granule (Prg1); septic 7 (cell div-
ision cycle 10 homolog) (Sept7); transcription elongation
factor B (SIII), polypeptide 1 (Tceb1); and transmembrane
protein 46 (Tmem46). However, in female mice, these
negative correlations did not show up. In addition, in male
mice, Egfr showed a positive correlation with membrane
Fig. 2 Expression levels of Egfr in kidney between female and male mice in BXD strains. Numbers on left vertical bar are for the relative levels of
expression of Egfr. The information of strains and names of standard inbred strains are listed under the horizontal bar. a. The expression levels of
Egfr in kidney of female mice. b. The expression levels of Egfr in kidney of male mice
Fig. 3 Gene network of Egfr in mouse Kidney. The 50 nodes in the graph below show the selected traits. Only nodes with edges are displayed.
The 208 edges between the nodes, filtered from the 1225 total edges and drawn as curves, show Pearson correlation coefficients greater than 0.5
or less than −0.5. The graph’s canvas is 40.0 by 40.0 cm, and the node labels are drawn with a 16.0 point font, and the edge labels are drawn
with a 16.0 point font. a. Gene network of top 50 genes that closely associated to Egfr in male mouse kidney. b. Gene network of male top 50
genes that closely associated to Egfr in female mouse kidney
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cofactor protein (Mcp); pleckstrin associated EST
AK008484 (Plek); and trinucleotide repeat containing 4
(Tnrc4), although this positive correlation did not show
up in female mice.
Confirmation of sex difference in kidney with multiple
probes
The above results are mainly based on Egfr probe
1460420. There were seven probes of Egfr on the Affy-
metrix Mouse Genome 430 2.0 array chip. In order to
find out whether these sex differences are caused by the
bias in one probe, we examined correlations between all
the Egfr probes and these groups of sex different genes.
We first obtained the data of all seven Egfr probes and
probes of all 11 genes that showed positive or negative
correlations with Egfr from kidney of male strains, and
then constructed the gene network for all of them. As
shown in Fig. 4a, three positive regulated genes (Mcp,
Plek, Tnrc4) were all being connected positively to at
least one of the Egfr probes, while eight negatively regu-
lated genes (Dock9, Clvs1, Fam162a, Nrp1, Prg1, Sept7,
Tceb1, Tmem46) were negatively connected to at least
one of the Egfr probes.
We next obtained the data of all seven Egfr probes and
probes of all above 11 genes from kidneys of female
mouse strains. Figure 4b showed that there was no
significant connection between these 11 genes to any
probe of Egfr. The R values were all under 0.3, at a non-
significant level. These data confirm the significant
difference in the molecular network of Egfr between
female and male mice.
EQTL regulation of Egfr between female and male mice
The eQTLs of all seven probes of Egfr in female and
male mice were identififed. Figure 5 shows the eQTL
mapped from each probe in female and in male mice.
The eQTL of these seven probes of Egfr in kidneys of
female mice were mapped on to chromosomes 1, 3, 9,
11, 12. 14, 15, 16 and 19. The probe, 1460420_a_at with
the highest expression level, was mapped on chromo-
some 14. The other probe, 1451530_ at, mapped an
eQTL on chromosome 15, with the highest LRS score of
15.6. We then found eQTLs for the regulation of Egfr
from the male kidney from these seven probes. The
eQTL from these probes were on chromosome 4, 9, 12,
14, 15, 17 and 19. The QTL with highest LRS value is
located on chromosome 4, which is 14.2 (Fig. 5).
Although there were overlaps on some chromosomes
of eQTL between female and male mice, the locations of
most of these eQTL are different between sexes. The
Fig. 4 Confirmation of negative and positive correlations between Egfr and key genes showing sex difference. The 18 nodes in the graph below
show the selected traits. The graph’s canvas is 40.0 by 40.0 cm, and the node labels are drawn with a 16.0 point font, and the edge labels are
drawn with a 16.0 point font. Curves show Pearson correlation coefficients greater than 0.3 or less than −0.3. a. Correlations between Egfr and key
genes in kidney of male mice. All nodes are displayed. The 73 edges between the nodes, filtered from the 153 total edges and drawn as curves.
b. Correlations between Egfr and key genes in kidney of female mice. Lack of positive and negative correlations between Egfr probes and 11 key
genes. All nodes are displayed. The 23 edges between the nodes, filtered from the 153 total edges and drawn as curves
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eQTLs from three probes were all different from each
other between female and male mice. Mapping with
probe 1424932_at, eQTLs were detected from chromo-
some 4 and 16 from female, while the eQTL was located
on chromosome 9 from the male. Mapping with probe
1435888_at, eQTLs were detected from chromosome 3
and 14 from female, while the eQTL was located on
chromosome 9 from the male. Mapping with probe
1457563_at, eQTLs were detected from chromosome 1
and 11 from female, while the eQTLs were mapped on
chromosome 9 and 17 from the male. The other two
probes each detected one overlapped eQTL and other
non-overlapped eQTLs between female and male. Map-
ping with probe 1432647_at, eQTLs were detected from
chromosomes 9 and 12 from female, while the eQTLs
were mapped on chromosomes 4 and 12 from the male.
Mapping with probe 1451530_at, eQTLs were detected
from chromosome 12, 15, and 19 from females, while
the eQTL were mapped on chromosomes 12 and 15
from the males. The final two probes had eQTL from
female but not from the male mice. Mapping with
probes 1454313_at and 1460420_a_at an eQTL was
detected on chromosome 14, for female for both probes,
while no eQTL was mapped from the male mice. Over-
all, the difference is much larger than the similarity.
Potential candidate for the Egfr expression level in male
mice on chromosome 4
According to the map based on probe #1432647, the peak
region of the eQTL on chromosome 4 is between
120.6 Mb and 124 Mb (Fig. 6a). Within the region, 35
genetic elements, including 25 known genes, exist. We
further examined the known SNP in this region among
BXD strains. Within the region, we find 13 polymorphic
markers between B6 and DBA/1. They are divided into 4
haploid groups. The first one is the SNP rs4224744, which
is located on 120.476225. The second group include
rs3675629 and gnf04.116.914, which located between
120.731447 Mb and 120.875373 Mb. The third group
includes 7 markers, gnf04.117.102, CEL-4_120039566,
Fig. 5 Detection of eQTL for regulation of Egfr expression levels in kidney of mouse RI strains using probes of Egfr. Top line is the numbers of Egfr
probes, second line is the eQTL detected from female mice. Bottom line shows the eQTL detected from male mice. The numbers on top of each
individual figure in second and bottom lines indicate the number of chromosome. Pink color lines on top of the individual figure indicate the
threshold for significant level. Light grey lines indicate the threshold for suggestive level
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UT_4_121.927901, gnf04.119.329, rs13477959, and
rs3714811, which is located between 121.069747 Mb
and 124.048406 Mb. The fourth group includes three
markers, rs3677161, rs13474356 and rs3704486, which is
located between 124.517595 Mb and 125.265631 Mb. We
then compared the expression level of Egfr with B (B6)
and D (DBA/1) genotypes in male mice of each group of
haploid types. The P values of T-test for each of these four
groups are 0.062186655, 0.035691806, 0.007229499, and
0.009439615, respectively (Fig. 6b). Thus, the candidate
genes are most likely located within the region covered by
the polymorphic markers in group 3. Within this region,
there are 29 genetic elements, Including 18 known genes.
These genes are Ppt1, Cap1, Mfsd2, Mycl1, Trit1, Bmp8b,
Oxct2b, Ppie, Hpcal4, Nt5c1a, Heyl, Pabpc4, Bmp8a,
Oxct2a, Macf1, Ndufs5, Rhbdl2, Mycbp and Rragc. We
next examined the relationship of expression level
between these candidate genes and that of Egfr. No ex-
pression level of these genes showed a strong correlation
to that of Egfr. In order to examine whether this eQTL is
male specific, we examined the Egfr expression of B and D
genotypes in female. Our data showed that the P values
between the B and D genotypes in different haploid
groups varied from 0.869525556 to 0.978478759 (Fig. 6c).
Thus, there is no difference in the Egfr expression level
between the B and D genotypes in female mice. These
data confirm the difference in the regulation of expression
levels of Egfr between female and male mice.
Potential impact of sex difference in Egfr expression on
immunological traits
Because of these sex differences, we expect some bio-
logical traits may be affected. In order to estimate the
potential impact of such a sex difference in the Egfr
expression on the immune system, we examined the
correlation between the Egfr expression level and some
available traits in GeneNetwork. While a majority of
the straits did not show a difference in terms of correl-
ation with the expression level of Egfr in both sexes,
some did show significant differences. Figure 6a and b
shows the significantly different effect of expression
level of Egfr between sexes on the level of interleukin-4
(Il4) from draining lymph node, 3 weeks post infection
(GeneNework ID: 12711). In the male, the expression
of Il4 is strongly positively correlated to that of Egfr,
(Fig. 7a) in female, with a Rho value of 0.929 for Spear-
man rank correlation. However, in the female, they are
negatively correlated (Fig. 7b) with a Rho value of
−0.445. Figure 7c and d shows the significantly different
effect of expression level of Egfr between sexes on the
level of alpha-aminoadipate levels measured by LC-MS/
MS in pooled plasma after overnight fasting in males at
29 weeks of age [33]. While in the male the expression
of alpha-aminoadipate is strongly negatively correlated
to that of Egfr with a Rho value of −0.721 (Fig. 7c), in
female they are weakly positively correlated with a Rho
value of 0.265 (Fig. 7d).
Potential sex difference in Egfr ligands
As function of Egfr is regulated by the availability of its
ligand, we further reexamined the expression levels of
two Egfr ligands, the heparin-binding epidermal growth
factor (hbEgf ) and Epithelial Mitogen (Epgn). The
eQTLs from two ligands were all different from each
other between female and male mice. Figure 8 shows the
eQTL detected from these two Egfr ligands. Mapping
with the probe from Epgn, 3 eQTLs at suggestive levels
were detected from chromosome 8, 13 and X from
female, while no eQTL was detected from the male.
Mapping with the probe from hbEgf, one eQTL at sig-
nificant level was detected from chromosome 18 from fe-
male, while an eQTL at suggestive level on chromosome 2
was detected from the male. These data strengthen the
importance of sex difference in drug design and treatment
when targeting at Egfr.
Discussion
Our data clearly demonstrated that there are sex differ-
ences in the molecular pathways of Egfr in the kidney.
Gene expression profiles from each RI strain are generated
from multiple homozygous mice [20–22, 29]. Female and
male mice in the same strains are kept in the same animal
facility with the same environment. The reliability of the
data was demonstrated by similar expression levels of
Actin B between female and male mice in these strains.
The significant sex difference in the expression levels of
Egfr in the kidney of these stains provided the solid foun-
dation for this important study. Accordingly, the informa-
tion on sex differences from these RI strains are important
resources for further study.
(See figure on previous page.)
Fig. 6 Comparison of level of Egfr expression of different genotypes in peak region of eQTL on chromosome 4. a. Location of peak region of
eQTL of Egfr in male mice. Pink color lines on top of the individual figure indicate the threshold for significant level. Light grey lines indicate the
threshold for suggestive level. Numbers on the Y bar are the LRS scores. Numbers on the X bar are the position on the chromosome measured
by Mb. b. The average expression levels of Egfr in male mice with BB and DD genotypes. Numbers on the Y bar are the relative expression levels
of Egfr. X bar indicates the groups of SNP and their genotypes. * P value is less than 0.05 but larger than 0.01. ** P values are less than 0.01. c. The
average expression levels of Egfr in female mice with BB and DD genotypes. Numbers on the Y bar are the relative expression levels of Egfr. X bar
indicates the groups of SNP and their genotypes
Liu et al. BMC Genetics  (2016) 17:146 Page 8 of 13
Majority sex differentially regulated genes from this
study have not been reported. However, a few of them
have demonstrated their important roles in the pathways
of Egfr. For example, NRP1 is widely expressed in cancer
cells and in advanced human tumors. Most importantly,
NRP1 is the co-receptor of EGFR [34]. It has been
reported that NRP1 can control EGFR signaling and
tumor growth [35]. The expression of Nrp1 is strongly
negatively associated with that of Egfr in female mice
but did not show a strong connection with Egfr in male
mice. In such a case, it is important to know whether
such a difference exists during tumor development in
human kidney. Accordingly, these differences should be
brought to attention for the development of drugs for
cancers targeting Egfr in kidney diseases. It is also
known that in humans VEGF signaling controls the
Gonadotropin-releasing hormone (GnRH) neurons sur-
vival via NRP1 [36]. Hormones play an important role in
the expression of VEGF as well as NRP1 [33–35]. The
significant difference in correlation with two important
traits to Egfr confirms that the sex difference may have a
significant impact on a significant number of traits in-
cluding the immune system. For the drug targeted Egfr
pathway, attention should be paid to the gender
Fig. 7 Correlation between the expression level of Egfr and known traits between male and female mice. a. Expression of Il-4 from draining
lymph node in male mice is strongly positively correlated to that of Egfr. Numbers on the Y bar indicate the expression levels of Egfr. Numbers on the X
bar indicate expression levels of Il-4. b. Expression of Il-4 in female and Egfr are weakly negatively correlated. Numbers on the Y bar indicate the expression
levels of Egfr. Numbers on the X bar indicate expression levels of Il-4. c. In the male the expression of alpha-aminoadipate is negatively correlated to that of
Egfr. Numbers on the Y bar indicate the expression levels of Egfr. Numbers on the X bar indicate expression levels of alpha-aminoadipate in male mice.
d. In the female the expression of alpha-aminoadipate and that of Egfr are weakly positively correlated. Numbers on the Y bar indicate the expression levels
of Egfr. Numbers on the X bar indicate expression levels of alpha-aminoadipate in female mice
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differences of the drug response in the clinical trials.
Dosages and methods of application of these drugs may
need to be modified based on the gender.
It is known that in humans EGFR is a hormone related
gene [27, 28]. It is reasonable to assume that its gender
differential regulation to a certain degree hormone rele-
vant. In addition to the Nrp1, we found that several other
differentially expressed genes between female and male
mice are also hormone related genes. For example, Prg1 is
a progestin-responsive gene [37]. In humans, TCEB1 pro-
motes invasion of prostate cancer cells and is involved in
the development of hormone-refractory prostate cancer
[38]. TSLP is involved in the regulation of estrogen on the
secretion of MCP-1 and IL-8, and the growth of ESCs
through JNK and NF-κB signal pathways [39, 40].
Interestingly, the eQTL that regulate the Egfr expression
levels between female and male mice showed significant
differences. Although several eQTL between mice are lo-
cated on the same chromosomes in both sexes, these same
eQTL are usually not being mapped with the same probes
between sexes. For example, eQTL on chromosome 4 was
mapped in females by probe 1424932_at while it was
mapped in males by probe 1432647_at. EQTL on chromo-
some 9 was mapped in females by probe 1432647_at while
it was mapped in males by probe 1424932_at, 1435888_at,
and 1457563_at. Furthermore, eQTL was mapped on
chromosome 14 by three probes 1435888_at, 1454313_at
and 1460420_a_at in females but not by any probe in male
mice. This complicated regulation of Egfr between females
and males suggest that it is very likely that various mecha-
nisms such as different splicing sites, multiple promote
sites as well as differences in binding sites may involve in
the regulation of Egfr. Further studies are necessary to
clarify their mechanisms.
Similarly, our data also showed that potentially the ex-
pression levels of many Egfr ligands and/or relevant
genes may also have sex-related differences. We demon-
strated that different eQTL regulate the sex difference of
hbEgf and Epgn. We believe that the expression of many
Egfr ligands may be regulated differently in females and
males. The sex differential expression may directly or
indirectly affect the disease incidents and response to
drug treatment. For example, hbEGF involves in kidney
diseases such as glomerulonephritis and diabetic kidney
disease [41, 42]. The interaction between Egfr and hbEgf
in females and males may play an essential role on the
effect of hbEgf on the diseases. Overexpression of Epgn
during embryonic development induces reversible, epi-
dermal growth factor receptor-dependent sebaceous
gland hyperplasia [43]. We also notice that although Egfr
is ubiquitously expressed [44, 45], its function is regu-
lated by its ligands which are highly spatially restricted.
Therefore further analysis of the sex differences of
expression of Egfr ligands is necessary.
Similar to our previous study, this study is that our ana-
lysis is at one time point [29]. The differentially expressed
genes between female and male mice may vary at different
life stages. Future studies at different ages may lead to a
comprehensive understanding of the sex difference in the
molecular pathways of the Egfr axis in kidney. Similar to
many studies, our data set is from the RI strains that were
derived from two mouse strains, C57BL/6 J and DBA/2 J.
Mouse strain specific pathways have been known [46, 47].
The results may represent sex difference under certain
Fig. 8 Detection of eQTL for regulation of Egfr ligands Epgn and hbEgf expression levels in kidney of mouse RI strains using probes of Egfr. The
number on top of each individual figure indicates the number of chromosome. Pink color lines on top of the individual figure indicate the threshold
for significant level. Light grey lines indicate the threshold for suggestive level. Numbers on the bottom indicate the Mb on the chromosomes
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genomic backgrounds. Studies using other strains may
reveal different mechanisms..
Like all other studies using animal models, the sex dif-
ferences from this study may or may not represent that in
humans [48]. Thus, not all the sex differentially expressed
genes in mouse kidney are differentially expressed be-
tween males and females in human kidney. However, this
study and our other study [29] strongly suggest that a gen-
der difference in the EGFR pathway in humans exists.
We understand that, although the RNA expression
levels are matched to the protein levels in a majority of
genes, in some cases, the gene expression level does not
necessarily represent the protein level. As to Egfr, a con-
siderable number of publications have indicated the
consistency between the RNA expression level and protein
level [49–51]. However, a relatively large number of genes
including its ligands are in the pathways in regulation of
Egfr. It is important to examine whether their RNA ex-
pression levels agree with their protein levels in the future.
On the other hand, the disagreement between protein and
RNA levels does not necessarily invalidate the importance
of the gene expression. We now know that RNA itself
plays an important role in many biological functions in-
cluding regulation of the expression of genes.
Conclusion
Our study reveals that there are differences in the mo-
lecular pathways of Egfr in the kidney between female
and male mice. Many of sex differential expressed genes
are related to hormone metabolism. These data reinforce
the importance of being aware of the gender difference
in drug development targeting Egfr and its ligands and
their pathways.
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